BAUSCH HEALTH AMERICAS, INC.
Randomised, Placebo-controlled Safety and Pharmacokinetics Study of Novel Rifaximin Formulations in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT04529811
- Locations
- 🇳🇿
Auckland Clinical Studies, Grafton, Auckland, New Zealand
Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Bausch Health Americas, Inc.
- Registration Number
- NCT04356677
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT04314375
- Locations
- 🇺🇸
Bausch Health Site 008, Garden Grove, California, United States
🇺🇸Bausch Health Site 003, Indianapolis, Indiana, United States
🇺🇸Bausch Health Site 006, Bronx, New York, United States
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT04214652
- Locations
- 🇺🇸
Bausch Site 212, Detroit, Michigan, United States
🇺🇸Bausch Site 203, Gresham, Oregon, United States
🇺🇸Bausch Site 204, Johnston, Rhode Island, United States
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 183
- Registration Number
- NCT04214639
- Locations
- 🇺🇸
Bausch Site 106, Sanford, Florida, United States
🇺🇸Bausch Site 110, Bryant, Arkansas, United States
🇺🇸Bausch Site 102, Boynton Beach, Florida, United States
A Study to Assess the Efficacy and Safety of Salix Probiotic Blend in Participants With Functional Gastrointestinal Disturbances
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 188
- Registration Number
- NCT04155801
- Locations
- 🇺🇸
Bausch Site 001, San Antonio, Texas, United States
An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Bausch Health Americas, Inc.
- Registration Number
- NCT04151719
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 252
- Registration Number
- NCT04149587
- Locations
- 🇨🇦
Bausch Site 002, Montréal, Manitoba, Canada
🇨🇦Bausch Site 001, Winnipeg, Manitoba, Canada
🇨🇦Bausch Site 014, North Bay, Ontario, Canada
A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Bausch Health Americas, Inc.
- Registration Number
- NCT04083651
- Locations
- 🇺🇸
Bausch Site 001, Omaha, Nebraska, United States
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT03988439
- Locations
- 🇺🇸
Bausch Site 3, Louisville, Kentucky, United States
🇺🇸Bausch Site 11, Mayfield Heights, Ohio, United States
🇺🇸Bausch Site 4, Murray, Utah, United States